The Cost-Effectiveness of Tradition Chinese Medicine Icaritin Versus Cinobufotalin in Patients with Unresectable Advanced Hepatocellular Carcinoma in China

Author(s)

Guo J1, Xuan J2, Zhuo Y3
1Shanghai Centennial Scientific Ltd, Toronto, ON, Canada, 2Health Economic Research Institute, School of Pharmacy, Sun Yat-sen University, Guangzhou, Guangdong, China, 3Health Economic Research Institute, School of Pharmacy, Sun Yat-Sen University, Guangzhou, Guangdong, China

Presentation Documents

OBJECTIVES: To evaluated the cost-effectiveness of patients with unresectable advanced hepatocellular carcinoma using traditional Chinese medicine Icaritin versus Cinobufotaline in China from societal perspective.

METHODS: A partitional survival model was conducted strictly followed by China Guidelines for Pharmacoeconomic Evaluations to evaluate the incremental cost-effectiveness ratio (ICER) of two medicine with a lifetime horizon. To fit parametric models, a log-normal was generated for Cinobufotaline’s overall survival (OS) and exponential distribution for Icaritin’s OS, an exponential distribution for progression free survival of both groups. The efficacy data input was collected from clinical trial SNG1705ICR-1. The utility data, probability of treatment related adverse events were collected from the literature. Cost inputs were derived from public database and the literature. Model robustness was assessed via one-way sensitivity and probabilistic sensitivity analyses.

RESULTS: Comparing with Cinobufotaline, Icaritin had a higher cost (¥192,462 versus ¥5,351) and longer life year (1.26 versus 0.77), quality-adjusted life years (QALY) gained of 0.46 (1.06 versus 0.60) over a lifetime horizon. Key drivers were the lower probability of adverse events and better clinical efficacy of Icaritin, the ICER of the baseline result was ¥358,709 per QALY gained.

CONCLUSIONS: Overall, from the societal perspective, Icaritin is likely to be a cost-effective option compared with Cinobufotaline for Chinese unresectable advanced hepatocellular carcinoma patients s. Meanwhile, inclusion of broader evidence on clinical efficacy using first-line therapy from real-world studies among Chinese population is suggested, which could solidate the economic evidence and further improve the use of Icaritin.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

EE77

Topic

Clinical Outcomes, Economic Evaluation, Methodological & Statistical Research

Topic Subcategory

Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×